Why Vala?

Vala enables drug developers to identify which lead candidates will cause side effects before in vivo animal testing, virtually eliminating a major cause of wasted time, money and resources.

The pharmaceutical industry evaluates millions of new drug targets and lead candidates every year in the hopes of finding a few that will survive the development gauntlet to mature into safe, effective medicines.

Unfortunately, the industry has been fighting an overwhelming battle of attrition. Throughout the development cycle, drug candidates fail due to safety concerns, inadequate efficacy and other reasons.

The longer a doomed candidate survives the development game, the higher the cost to the industry, both financially and in lost time.

Failure Rate in Clinic
0 Years
Typical Development Time
Development Cost

“Fail Fast” to mitigate the Strain of Attrition Costs

Through our KIC® technology and CyteSeer® software, Vala can achieve in vitro screening predictivity unmatched by other in vitro methods.  In fact, Vala’s methods have been demonstrated to be equivalent to in vivo animal testing in some cases.

  • Demote candidates with observed cardiotoxicity or neurotoxicity

  • Promote candidates with excellent safety profiles

  • Statistically rank candidates by efficacy much earlier (before clinic)

  • Down-select candidates with higher probability of successful clinical development.

The objective of Vala’s predictive screening services is to help drug developers statistically rank order their portfolios early in the game, well before they get to the clinic.

Candidates with observed cardiotoxicity or neurotoxicity can be demoted while candidates with excellent safety profiles can move to the top of the list for further screening. In some areas, Vala can also screen for drug efficacy, enabling the industry to remove ineffective candidates before they fruitlessly consume precious resources.

Arrhythmia and Cardiomyopathy are Leading Causes of Post-Approval Drug Withdrawals

Cardiosafety Failures Pie Chart

Causes of 65 Drugs Withdrawn for Cardiosafety Reasons

Of the 353 medicinal products withdrawn from sale in 1950-2015, cardiovascular, hepatic, and nervous system toxicities accounted for 60% of post-marketing failure. Attrition due to cardiovascular problems (22%) was reported to exceed those of hepatotoxicity (21%) throughout the drug development process (preclinical to marketing/post-approval). Adverse drug reactions from Phase I clinical trials through post-approval due to cardiovascular side effects (16%) exceeded those due to hepatotoxicity (1%).

Recent studies of post-approval drug withdrawals due to cardiovascular safety issues report 74% of such withdrawals were due to primary cardiac toxicities, with 35% caused by arrhythmias, 38% caused by cardiac injury (cardiomyopathy) and 22% due to cardiovascular events (see pie chart).

Interested in Learning More?

Please use this form to email Vala, or call today at (888) 742-VALA (8252).